Denosumab is a medication that works by blocking a protein involved in bone loss. It is commonly used to treat osteoporosis and prevent bone-related complications. In this trial, researchers are studying how this medication might affect muscle strength and how the body processes insulin (insulin sensitivity). It is given as an injection under the skin.

Diabetes Mellitus – A chronic metabolic disorder characterized by high blood sugar levels due to the body’s inability to produce enough insulin or use it effectively. The condition affects how the body processes glucose, which is vital for energy production in cells. Over time, the pancreas may produce less insulin, or body cells become resistant to insulin’s effects. The disease can develop gradually, often with subtle initial symptoms such as increased thirst, frequent urination, and fatigue.

Postmenopausal Osteoporosis – A condition that occurs in women after menopause, characterized by decreased bone density and increased bone fragility. The condition develops when bone breakdown occurs faster than bone formation, leading to progressive loss of bone mass. This process accelerates after menopause due to decreased estrogen levels. The bones become more porous and weaker over time, making them more susceptible to structural changes.